Key facts
- This page summarizes Peter Behner's Form 3 filing for MiNK Therapeutics, Inc. (INKT).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 Oct 2021, 18:55.
Peter Behner - 13 Oct 2021 Form 3 Insider Report for MiNK Therapeutics, Inc. (INKT)
- Reporting relationship
- Director
- Issuer ticker
- INKT
- Reported as of
- 13 Oct 2021
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 20 Oct 2021, 18:55:03 UTC
- Next SEC filing
- 11 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christine Klaskin, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Peter Behner filed Form 3 for MiNK Therapeutics, Inc. (INKT) on 20 Oct 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INKT
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 13 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 41,745
- Exercise price
- $3.03
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents an option to purchase shares of the common stock, which vests in three equal annual installments beginning on April 1, 2022.
SEC remarks
Exhibit List: Exhibit 24 - Power of Attorney